82938-49-6

Upstream product

• 2886-33-1 dibenzyl L-aspartate toluene-4-sulphonate 
• 2791-79-9 dibenzyl L-aspartate 
• 72776-06-8 (L)-N-(trimethylsilyl)dibenzyl aspartate 
• 18162-48-6 tert-butyldimethylsilyl chloride 
• 72776-05-7 (S)-benzyl 4-oxoazetidine-2-carboxylate 
• 130540-09-9 dibenzyl (S)-2-(tert-butyldimethylsilylamino)succinate 

Downstream Products

• 82938-50-9 (4S)-N-tert-butyldimethylsilylazetidin-2-one-4-carboxylic acid 
• 158419-31-9 menthyl N-<1-tert-butyldimethylsilyl-2-azetidinone-4-carboxy>glycinate 
• 193959-27-2 (2S,3S)-1-[2-(3-Benzyloxycarbonyl-phenyl)-acetyl]-3-(4-hydroxy-benzyl)-4-oxo-azetidine-2-carboxylic acid benzyl ester 
• 193959-26-1 (3S,4S)-3-[4-[(1,1-dimethylethyl)diphenylsilyloxy]phenylmethyl]-4-benzyloxycarbonylazetidin-2-one 
• 342624-75-3 (3S,4S)-4-benzyloxycarbonyl-1-[3'-(benzyloxycarbonyl)phenylacetate]-3-[4'-(tert-butyldiphenylsilyloxy)benzyl]-2-azetidionone 
• 193959-25-0 (3S,4S)-4-benzyloxycarbonyl-1-(tert-butyldimethylsilyl)-3-[4'-(tert-butyldiphenylsilyloxy)benzyl]-2-azetidinone 

Relevant academic research and scientific papers

OBTENTION D'UN α-AMINO ALDEHYDE PTIQUEMENT ACTIF EN SERIE β-LACTAME

Oxidation of a suitable protected L-aspartic acid derived azetdione gives rise to a chiral β-lactam carboxaldehyde without significant racemization.

QUATERNARY LACTAM COMPOUND AND PHARMACEUTICAL USE THEREOF

A quaternary lactam compound of formula (I). The compound is used in the manufacture of a medicament for the treatment and/or prevention of thrombotic or thromboembolic disorders.

The discovery and optimization of benzimidazoles as selective NaV1.8 blockers for the treatment of pain

The voltage gated sodium channel NaV1.8 has been postulated to play a key role in the transmission of pain signals. Core hopping from our previously reported phenylimidazole leads has allowed the identification of a novel series of benzimidazole NaV1.8 blockers. Subsequent optimization allowed the identification of compound 9, PF-06305591, as a potent, highly selective blocker with an excellent preclinical in vitro ADME and safety profile.

Stereoselective Synthesis of Tricyclic Diproline Analogues that Mimic a PPII Helix: Structural Consequences of Ring-Size Variation

Polycyclic proline-derived scaffolds (ProMs) have recently demonstrated their value as conformationally defined dipeptide analogs for the modular construction of secondary structure mimetics, specifically interfering with PPII helix-mediated protein-protein interactions. We disclose the stereoselective synthesis of two new tricyclic amino acid scaffolds (ProM-4 and ProM-8) that differ from the first generation scaffold ProM-1 by the size of ring A. Conformational preferences and subtle structural differences of the three homologous scaffolds were analyzed by X-ray crystallography, computational calculations, and NMR spectroscopy. N-tert-butoxycarbonyl(Boc)-3-(1-propenyl)azetidine-2-carboxylic acid was prepared from L-aspartic acid through β-lactam intermediates. The corresponding piperidine-based building block rac-N-Boc-3-vinylpipecolic acid was synthesized by Cu-catalyzed 1,4-addition of vinyl-MgBr to methyl N-Boc-2,3-dehydropipecolate. Target molecules were prepared through peptide coupling of the respective ring A building blocks with cis-5-vinylproline tert-butyl ester and subsequent ring-closing metathesis. Selective deprotection of a tert-butyl carbamate (N-Boc protecting group) in the presence of a tert-butyl ester was achieved with trifluoroacetic acid at 0 C. Two new tricyclic amino acid scaffolds, which differ from the first generation scaffold by the size of ring A, were stereoselectively synthesized. The conformational analysis of the three homologous scaffolds was revealed by NMR spectroscopy.

Cyclic dipeptides and azetidinone compounds and their use in treating CNS injury and neurodegenerative disorders

The present invention provides 4-substituted-2-azetidinone compounds, bicyclic 2-5-diketopiperazine compounds, and pharmaceutical compositions thereof that are potent, safe and effective neuroprotective agents. Due to their strong central nervous system (CNS) activity, the compounds can be used to enhance memory and to treat a variety of neurological disorders. The compounds are particularly useful for treating neurological disorders caused by, or associated with, CNS trauma.

β-Lactam derivatives as enzyme inhibitors: N-substituted derivatives of (S)-4-oxoazetidine-2-carboxylate as inhibitors of elastase and papain

N-Alkyl and N-acyl substituted 4-oxoazetidine-2-carboxylates are synthesized and evaluated as inhibitors of the proteases porcine pancreatic elastase (PPE) and papain. The compounds are obtained by alkylation or acylation at the nitrogen of benzyl (S)-4-oxoazetidine-2-carboxylate, which is synthesized by a modified literature procedure. The enzymatic assays prove some derivatives to be effective inhibitors of PPE and/or papain. The N-BOC protected amino acid derivatives 10 and 13 inhibit PPE reversibly with K(I)-values in the micromolar range. On the other hand, papain is inactivated irreversibly by benzyl (S)-2-(benzyloxycarbonyl)azetidin-1-acetate (6).

A synthesis of the platelet aggregation inhibitor xemilofiban from L- aspartic acid. Confirmation of the absolute configuration

A synthesis of xemilofiban (SC-54684A) from L-aspartic acid has been achieved in an overall yield of 18%, and the absolute configuration has been confirmed.

Design and synthesis of novel monocyclic β-lactam inhibitors of prostate specific antigen

A novel series of monocyclic β-lactam analogues was designed using a homology derived model of prostate specific antigen (PSA) and by application of a multiple copy simultaneous search technique. Syntheses were conducted by assembly of the β-lactam core v

Synthesis and biology of the rigidified glutamate analogue, trans-2-carboxyazetidine-3-acetic acid (t-CAA)

Chemical approaches to the (-)- and (+)-trans-2-carboxyazetidine-3-acetic acids (-)-1 and (+)-1, and their homologues (-)-2 and (+)-2, compounds that represent rigidified analogues of glutamate (glu), are reported together with the complete biological characterization of (+)-1 (t-CAA) at the known glu recognition sites. t-CAA was found to be an inhibitor of Na+-dependent glu uptake and to act as a kainate receptor ligand.

Studies on the Alkylation of Dipeptide Substrates

Alkylation of anions derived from dipeptides with a glycine at the C-terminus have been investigated.A hydrocarbon sedition in the N-terminal residue does impart some asymmetric induction.The use of a chiral ester derivative provides the potential for double asymmetric induction and good selectivity.With an aspartyl residue at the N-terminus, problems were encountered due to competing side reactions.The use of an azetidione could circumvent some of these, but the observed induction was not high.